Helix BioPharma Corp. Announces That Institutional ShareholderServices Recommends Shareholders Vote for Management's DirectorNominees
Helix BioPharma Corp. / Key word(s): Miscellaneous
23.01.2012 22:53
---------------------------------------------------------------------------
AURORA, ON -- (Marketwire) -- 01/23/12 -- Helix BioPharma Corp.
(TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) ('Helix,' 'HBP' or 'the
Company') is pleased to announce that Institutional Shareholder
Services ('ISS') has recommended that shareholders vote FOR the slate
of directors nominated by management, which includes Jack M. Kay, W.
Thomas Hodgson, Donald H. Segal, Ewa Don-Siemion, Wojciech M. Kwiatek
and Wayne Schnarr, at the upcoming annual meeting ('AGM') on January
30, 2012.
ISS is a leading independent international corporate governance
analysis and proxy voting firm. Its recommendations assist
shareholders in making decisions regarding proxy voting. In their
analysis, ISS stated:
'Ultimately we are not convinced that wholesale board change is
warranted at this time. Furthermore, it is not obvious that the
dissident nominees would be better able to create value than the
current board.'*
ISS also said: 'No major strategic missteps are apparent. On balance,
management appears to be taking steps to execute a reasonable plan.
The management nominees are recently refreshed with 3 new independent
candidates. In the circumstances, we are willing to give the
incumbents the benefit of the doubt and believe that shareholders can
give management more time to deliver on the strategy.'*
'We are pleased that ISS supports our view that the current directors
and management nominees are best suited to continue our work and
further establish Helix as a leading developer of clinically proven,
innovative cancer therapies,' said Donald H. Segal, CEO and Director
of Helix. 'We will continue to represent the interests of ALL
shareholders.'
Shareholders are reminded to vote their BLUE proxy well in advance of
the 10:00 a.m. (Toronto Time) January 26, 2012 proxy deadline.
If you have any questions regarding voting your BLUE proxy or require
assistance in voting your proxy, please contact Kingsdale Shareholder
Services Inc., at 1-866-879-7649 (toll free) or 416-867-2272 (outside
of North America) or by e-mail at contactus@kingsdaleshareholder.com.
*Permission to quote from the ISS report was neither sought nor
obtained.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company mainly focused
in the field of cancer therapy. The Company is actively developing
innovative products for the prevention and treatment of cancer based
on its proprietary technologies. Helix's product development
initiatives include its Topical Interferon Alpha-2b and its novel
L-DOS47 new drug candidate. Helix is listed on the TSX, NYSE Amex and
FSE under the symbol 'HBP.' For more information, please visit
www.helixbiopharma.com.
Forward-Looking Statements and Risks and Uncertainties
This News Release contains forward-looking statements and
forward-looking information (collectively, 'forward-looking
statements'), within the meaning of applicable securities laws
regarding the development of products by Helix for the prevention and
treatment of cancer based on its proprietary technologies; ISS's
recommendations; and the plans of the current directors and
management nominees to establish Helix as a leading developer of
cancer therapies. The use of any of the words 'continue,' will,'
'believe,' and 'execute' and similar expressions are intended to
identify forward-looking statements. Certain material factors or
assumptions are applied in making forward-looking statements,
including, but not limited to, the continued recommendation of ISS for
shareholders to support the slate of directors nominated by
management and the election of the management slate of director
nominees; the timely receipt of necessary additional funding,
strategic partner support and regulatory approvals; the safety and
efficacy of the Company's drug candidates; the timely provision of
services and performance of contracts by third parties; and future
revenue, costs and expenditures. Helix's actual results could differ
materially from those anticipated in these forward-looking statements
as a result of numerous risks and uncertainties including without
limitation, the election of the dissident shareholders' nominees to
Helix's board of directors and uncertainty surrounding those
nominees' plans for the Company, if elected; the outcome of the
Company's upcoming annual general meeting; the risk that ISS may
change its recommendation prior to the AGM; uncertainty of the
availability of needed capital; uncertainty whether the Company's
drug candidates under development will be successfully developed and
commercialized; whether clinical trials will proceed as planned or at
all, and the risk of negative results; research and development
risks, including, but not limited to, manufacturing risks and reliance
on third-party service providers; insurance and intellectual property
risks; the effect of competition; the risk of technical obsolescence;
uncertainty about the market opportunity for Helix's products;
uncertainty whether the Company will be able to obtain an appropriate
pharmaceutical or strategic partner for the drug candidates; changes
in business strategy or plans; general economic conditions; and the
risk factors that are discussed under Item 3.D. - 'Risk Factors' in
the Company's latest Form 20-F Annual Report or identified in the
Company's other public filings with the Canadian securities
administrators at www.sedar.com or with the SEC at www.sec.gov.
Forward-looking statements and information are based on the beliefs,
assumptions and expectations of Helix's management at the time they
are made, and Helix does not assume any obligation to update any
forward-looking statement or information should those beliefs,
assumptions or expectations, or other circumstances change, except as
required by law.
News Source: Marketwire
23.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Helix BioPharma Corp.
Canada
Phone:
Fax:
E-mail:
Internet:
ISIN: CA4229101098
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Helix BioPharma Corp. / Key word(s): Miscellaneous
23.01.2012 22:53
---------------------------------------------------------------------------
AURORA, ON -- (Marketwire) -- 01/23/12 -- Helix BioPharma Corp.
(TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) ('Helix,' 'HBP' or 'the
Company') is pleased to announce that Institutional Shareholder
Services ('ISS') has recommended that shareholders vote FOR the slate
of directors nominated by management, which includes Jack M. Kay, W.
Thomas Hodgson, Donald H. Segal, Ewa Don-Siemion, Wojciech M. Kwiatek
and Wayne Schnarr, at the upcoming annual meeting ('AGM') on January
30, 2012.
ISS is a leading independent international corporate governance
analysis and proxy voting firm. Its recommendations assist
shareholders in making decisions regarding proxy voting. In their
analysis, ISS stated:
'Ultimately we are not convinced that wholesale board change is
warranted at this time. Furthermore, it is not obvious that the
dissident nominees would be better able to create value than the
current board.'*
ISS also said: 'No major strategic missteps are apparent. On balance,
management appears to be taking steps to execute a reasonable plan.
The management nominees are recently refreshed with 3 new independent
candidates. In the circumstances, we are willing to give the
incumbents the benefit of the doubt and believe that shareholders can
give management more time to deliver on the strategy.'*
'We are pleased that ISS supports our view that the current directors
and management nominees are best suited to continue our work and
further establish Helix as a leading developer of clinically proven,
innovative cancer therapies,' said Donald H. Segal, CEO and Director
of Helix. 'We will continue to represent the interests of ALL
shareholders.'
Shareholders are reminded to vote their BLUE proxy well in advance of
the 10:00 a.m. (Toronto Time) January 26, 2012 proxy deadline.
If you have any questions regarding voting your BLUE proxy or require
assistance in voting your proxy, please contact Kingsdale Shareholder
Services Inc., at 1-866-879-7649 (toll free) or 416-867-2272 (outside
of North America) or by e-mail at contactus@kingsdaleshareholder.com.
*Permission to quote from the ISS report was neither sought nor
obtained.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company mainly focused
in the field of cancer therapy. The Company is actively developing
innovative products for the prevention and treatment of cancer based
on its proprietary technologies. Helix's product development
initiatives include its Topical Interferon Alpha-2b and its novel
L-DOS47 new drug candidate. Helix is listed on the TSX, NYSE Amex and
FSE under the symbol 'HBP.' For more information, please visit
www.helixbiopharma.com.
Forward-Looking Statements and Risks and Uncertainties
This News Release contains forward-looking statements and
forward-looking information (collectively, 'forward-looking
statements'), within the meaning of applicable securities laws
regarding the development of products by Helix for the prevention and
treatment of cancer based on its proprietary technologies; ISS's
recommendations; and the plans of the current directors and
management nominees to establish Helix as a leading developer of
cancer therapies. The use of any of the words 'continue,' will,'
'believe,' and 'execute' and similar expressions are intended to
identify forward-looking statements. Certain material factors or
assumptions are applied in making forward-looking statements,
including, but not limited to, the continued recommendation of ISS for
shareholders to support the slate of directors nominated by
management and the election of the management slate of director
nominees; the timely receipt of necessary additional funding,
strategic partner support and regulatory approvals; the safety and
efficacy of the Company's drug candidates; the timely provision of
services and performance of contracts by third parties; and future
revenue, costs and expenditures. Helix's actual results could differ
materially from those anticipated in these forward-looking statements
as a result of numerous risks and uncertainties including without
limitation, the election of the dissident shareholders' nominees to
Helix's board of directors and uncertainty surrounding those
nominees' plans for the Company, if elected; the outcome of the
Company's upcoming annual general meeting; the risk that ISS may
change its recommendation prior to the AGM; uncertainty of the
availability of needed capital; uncertainty whether the Company's
drug candidates under development will be successfully developed and
commercialized; whether clinical trials will proceed as planned or at
all, and the risk of negative results; research and development
risks, including, but not limited to, manufacturing risks and reliance
on third-party service providers; insurance and intellectual property
risks; the effect of competition; the risk of technical obsolescence;
uncertainty about the market opportunity for Helix's products;
uncertainty whether the Company will be able to obtain an appropriate
pharmaceutical or strategic partner for the drug candidates; changes
in business strategy or plans; general economic conditions; and the
risk factors that are discussed under Item 3.D. - 'Risk Factors' in
the Company's latest Form 20-F Annual Report or identified in the
Company's other public filings with the Canadian securities
administrators at www.sedar.com or with the SEC at www.sec.gov.
Forward-looking statements and information are based on the beliefs,
assumptions and expectations of Helix's management at the time they
are made, and Helix does not assume any obligation to update any
forward-looking statement or information should those beliefs,
assumptions or expectations, or other circumstances change, except as
required by law.
News Source: Marketwire
23.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Helix BioPharma Corp.
Canada
Phone:
Fax:
E-mail:
Internet:
ISIN: CA4229101098
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------